Use of Neurofilament Light Chain (NfL) as a Biomarker in Multiple Sclerosis (MS)
May 18th 2023Bruce Hughes, MD, provides an overview of the use of neurofilament light chain (NfL) as a biomarker in multiple sclerosis (MS), highlighting the accuracy and reliability of plasma/serum NfL (pNfL) and cerebrospinal fluid (CSF) NfL measurements.
COVID-19 Severity in Pediatric Patients With MS on B-Cell-Depleting Therapies: Teri Schreiner, MD
May 18th 2023The associate professor at the University of Colorado talked about a study involving pediatric patients with multiple sclerosis and related disorders, and the risk of COVID-19 infection among those on B-cell-depleting therapy. [WATCH TIME: 5 minutes]
Exploring the Risk of Hypertension Following Erenumab Treatment for Migraine: Nikita Chhabra, DO
May 17th 2023The neurology PGY-3 at Mayo Clinic in Arizona talked about findings from a retrospective cohort study that examined blood pressure in patients who were prescribed a migraine medication. [WATCH TIME: 6 minutes]
Success of Ravulizumab Through the Phase 3 CHAMPION-NMOSD Trial: Sean Pittock, MD
May 16th 2023The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed findings from the phase 3 CHAMPION-NMOSD trial of ravulizumab in patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 5 minutes]
Efficacy of Remote Neuromodulation for Migraine Prevention: Stewart J. Tepper, MD
May 15th 2023At the 2023 AAN Annual Meeting, the professor of neurology at the Geisel School of Medicine at Dartmouth talked about the effectiveness of a remote electrical neuromodulation device that offers potential relief for both episodic and chronic migraine. [WATCH TIME: 3 minutes]
Effectiveness of Zavegepant in Treating Migraine With and Without Aura: Timothy Smith, MD
May 10th 2023The chief executive officer and president of Study Metrics Research provided commentary on a large-scale analysis further demonstrating efficacy and safety of zavegepant, regardless of aura status. [WATCH TIME: 3 minutes]
Narrowing Down Effective Medications, Classes of Treatments for Migraine: Chia-Chun Chiang, MD
May 9th 2023The associate professor of neurology at Mayo Clinic Rochester discussed specific findings from a simultaneous comparison of migraine medications in which certain treatments and classes were more effective. [WATCH TIME: 3 minutes]
Unmet Needs and Improving Diagnosis of Dyskinesia in Parkinson Disease
The expert panel reviews unmet needs in treatment and management of dyskinesia and shares advice for physicians treating patients with Parkinson disease.
Surgical Options and Emerging Treatments for Parkinson Disease
Drs Fernando Pagan, Robert A. Hauser, and Daniel Kremens highlight existing and emerging surgical and pharmacological options for treatment of dyskinesia in Parkinson disease.